Brought to you by 
Global Blood nets $112.8mm through public offering
22 Jun 2016
Executive Summary
Global Blood Therapeutics Inc. (developing treatments for blood-based diseases) netted $112.8mm through a public sale of 6.4mm common shares at $18.75. Proceeds will fund development activities, including completion of Phase I/II trials with GBT440 for sickle cell disease; planned trials for GBT440 for idiopathic pulmonary fibrosis and other hypoxemic pulmonary disorders; and initiation of development of GBT018713 for the treatment of hereditary angioedema.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Global Blood nets $112.8mm through public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice